Brief report: Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 5, 2001, Pages 462-465

  Sabin, Caroline A ^a   Fisher, Martin ^b   Churchill, Duncan ^b,c   Pozniak, Anton ^d   Hay, Phillip ^e   Easterbrook, Philippa ^f   Williams, Ian ^g  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Brighton Hlthcare Natl Hlth S   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e ST GEORGE S HOSPITAL   (United Kingdom)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; UNITED KINGDOM; VIRUS LOAD; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0035870528     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200104150-00009     Document Type: Article

References (14)

1. D'Aquila RT, Hughes MD, Johnson WA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996;124:1019-30.
2. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA 1998; 279:930-7.
3. Floridia M, Bucciardini R, Ricciardulli D, et al. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naïve patients with advanced disease. J Acquir Immune Defic Syndr 1999;20:11-19.
4. de Jong MD, Vella S, Carr A. et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997;175:966-70.
5. Carr A, Vella S, de Jong MD, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group. AIDS 1996;10:635-41.
6. Fisher MJ, Pozniak AL, Churchill DR, et al. The efficacy and safety of nevirapine (NVP) in clinical practice: experience in over 500 patients in the UK [abstract 32248]. XII World Conference on AIDS, Geneva, Switzerland, June 28-July 3, 1998.
7. Notermans D, Jurriaans S, de Wolf F, et al. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. AIDS 1998;12: 167-73.
8. Clumeck N for the AVANTI Study Group. A randomized, double blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs. AZT/3TC/NFV in antiretroviral naïve patients [abstract 8]. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, U.S.A., February 1-5, 1998.
9. Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999;13: 367-73.
10. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
11. Raboud J, Montaner JSG, Rae S, et al. Patients with higher baseline pVL are less likely to have a virologic response in a meta-analysis of two trials of ZDV/ddI vs ZDV/ddI/NVP [abstract 12361]. XII World Conference on AIDS, Geneva, Switzerland, June 28-July 3, 1998.
12. Hay P, Mitchla Z: British HIV Association guidelines [letter]. Lancet 1998,352:1226.
13. Pollard R. Factors predictive of durable HIV suppression in randomized double-blind trial with nevirapine (NVP), zidovudine (ZDV), and lamivudine (3TC) in treatment-naïve (ARV-n) patients with advanced AIDS [abstract 517]. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, U.S.A., January 30-February 2, 2000.
14. Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998;12:1619-24.